Vanda Pharmaceuticals' NEREUS™ Gains FDA Approval for Motion Sickness

Vanda Pharmaceuticals shares are trading higher after announcing FDA approval of their new motion sickness drug, NEREUS™, and following Jefferies' price target upgrade to $7.50 from $5.